spacer
home > ict > autumn 2016 > can you resist?
PUBLICATIONS
International Clinical Trials

Can You Resist?

Alexander Fleming – who is credited with creating the first antibiotic, penicillin, in 1928 – cautioned as long ago as 1945: “There is the danger that the ignorant man may easily underdose himself and by exposing his microbes to nonlethal quantities of the drug make them resistant.” The O’Neill Commission on anti-microbial resistance (AMR) reported in 2015 that if we fail to act on AMR, then an additional 10 million lives would be lost each year to drugresistant strains of certain bacterial infections by 2050, at a cost to the world economy of $100 trillion.

In September, 193 UN member states agreed to combat the proliferation of drug-resistant infections, currently estimated to kill more than 700,000 people each year. At the 68th World Health Assembly in May 2015, a global action plan to tackle AMR was endorsed. To achieve the aforementioned goal, it set out five strategic objectives:
  • To improve awareness and understanding of AMR
  • To strengthen knowledge through surveillance and research
  • To reduce the incidence of infection • To optimise the use of antimicrobial agents
  • To develop the economic case for sustainable investment that takes into account the needs of all countries, and increase investment in new medicines, diagnostic tools, vaccines and other interventions
By contrast, an analysis released in November last year by the Tufts Centre for the Study of Drug Development estimated the average cost to produce a medication as about $2.6 billion, taking 10-15 years to accomplish. As I have previously remarked, there is little incentive for businesses to develop new antibiotics, since their use will be restricted so that resistance will not be built up. As an example, by 2013, the number of international pharmaceutical companies developing antibiotics had dwindled to just four.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

spacer
Graham Hughes
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPhI expert forecasts ‘huge growth in Middle East manufacturing with Europe a medium-term target’

CPhI Middle East & Africa (CPhI MEA) expert Madhukar Tanna, Chief Executive Officer of Pharmax, a United Arab Emirates (UAE) based branded generic manufacturer, says favourable conditions in the UAE are resulting in a boom of pharmaceutical manufacturing throughout the region. Government incentive schemes to increase domestic production, coupled with a brand friendly environment and rising healthcare needs is fuelling surging demand – with many new companies and plants launching in the last two years alone.
More info >>

White Papers

Clinical Research in Spain

BioClever

This whitepaper is on clinical research in Spain, giving a general outline of the main characteristics of research in this country and an overview of the applicable regulations, along with the reasons why Spain is a good place to do research.
More info >>

 
Industry Events

World Pharma Week 2019

17-20 June 2019, Seaport World Trade Center, Boston

World Pharma Week will bring together a unique and international mix of large and medium pharmaceutical and biotech companies, CROs, leading universities and clinical research institutions, emerging companies and tool providers—making it a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement